Rehnke Robert D, Clarke John M, Goodrum Aaron J, Badylak Stephen F
From Private Practice of Plastic Surgery, St. Petersburg, Fla.
Private Practice of General Surgery, St. Petersburg, Fla.
Plast Reconstr Surg Glob Open. 2024 May 17;12(5):e5821. doi: 10.1097/GOX.0000000000005821. eCollection 2024 May.
Few series report on using fat grafting as the primary form of breast reconstruction. A 9-year experience with absorbable biosynthetic scaffolds, used in place of silicone implants, for breast reconstruction is reviewed.
A clinical quality improvement approach was used to evaluate real-world data on a single plastic surgeon's experience treating breast reconstruction patients over a 7-year period.
Fifty-three patients had 74 breasts reconstructed, (following 51 therapeutic mastectomies and 23 prophylactic). Five of the 51 breasts (9.80 %) developed a local recurrence (mean follow-up of 4.5-5.5 years). This compared favorably with the practice's previous 6 years of silicone reconstructions. The most common complications were benign fat necrosis and oil cysts. More than 100 radiologic examinations were performed without interference by the absorbable implants. By 12-18 months post implantation, very little immune response was seen on histologic examinations of the biosynthetic scaffold constructs. Mature collagen and robust vascularity characterized the "mesh zone," whereas regenerated adipose tissue was seen in between and on top of the folded sheets of the implants. The average number of fat graft sessions in immediate reconstructions was 2.3, with a mean total fat graft volume of 551 mL, to restore an average mastectomy defect volume of 307 mL. Aesthetic outcomes were much better in the immediate reconstruction of nipple-sparing mastectomy group, which saw 68% achieve an A/B grade; 19%, C grade; and 13%, D/F on subjective grading.
This composite strategy, using biosynthetic scaffold and autologous fat grafting, yielded outcomes equivalent to flap reconstructions with the ease of implants.
很少有系列报道将脂肪移植作为乳房重建的主要形式。本文回顾了使用可吸收生物合成支架替代硅胶植入物进行乳房重建的9年经验。
采用临床质量改进方法来评估一位整形外科医生在7年期间治疗乳房重建患者的真实世界数据。
53例患者共74个乳房进行了重建(51例治疗性乳房切除术和23例预防性乳房切除术后)。51个乳房中有5个(9.80%)出现局部复发(平均随访4.5 - 5.5年)。这与该机构此前6年的硅胶重建相比具有优势。最常见的并发症是良性脂肪坏死和油囊肿。进行了100多次放射学检查,未受到可吸收植入物的干扰。植入后12 - 18个月,在生物合成支架结构的组织学检查中未见明显免疫反应。“网眼区”以成熟的胶原蛋白和丰富的血管为特征,而在植入物折叠片之间和顶部可见再生脂肪组织。即刻重建中脂肪移植的平均次数为2.3次,平均总脂肪移植量为551 mL,以恢复平均乳房切除缺损量307 mL。保留乳头的乳房切除即刻重建组的美学效果要好得多,主观分级中68%达到A/B级;19%为C级;13%为D/F级。
这种使用生物合成支架和自体脂肪移植的复合策略,产生的效果等同于皮瓣重建,且具有植入物的便利性。